Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3755 - A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: a GISCAD trial.


29 Sep 2019


Poster Display session 2


Tumour Site

Gastric Cancer


Roberto Labianca


Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247


R. Labianca1, G. Rosati2, N. Fazio3, L. Cavanna4, D. Ferrari5, M. Di Bartolomeo6, S. Mosconi7, M. Giordano8, N. Silvestris9, F. Artioli10, R.V. Iaffaioli11, E.A. Veltri12, D. Amoroso13, A. Ciarlo14, S. Barni15, S. Cascinu16, C. Davite17, A. Di Sanzo17, A. Casolaro17

Author affiliations

  • 1 Oncologia Medica, Azienda Ospedaliera Papa Giovanni XXIII, 24127 - Bergamo/IT
  • 2 Medical Oncology, A.O. S.Carlo, 85100 - Potenza/IT
  • 3 Unit Of Gastrointestinal Medical Oncology And Neuroendocrine Tumors, Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 4 Oncology Department, Azienda Ospedaliera Piacenza, 29121 - Piacenza/IT
  • 5 Oncologia Medica, A. O. San Paolo, 20142 - Milano/IT
  • 6 Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, 20133 - Milan/IT
  • 7 Oncologia Medica, A.O. Papa Giovanni XXIII, 24127 - Bergamo/IT
  • 8 Oncologia Medica, Presidio Ospedaliero Ospedale Sant'Anna, 22100 - San Fermo della Battaglia/IT
  • 9 Medical Oncology Unit, Istituto Tumori Giovanni Paolo II, 70126 - Bari/IT
  • 10 Ausl Modena, Ospedale Ramazzini, 41015 - Carpi/IT
  • 11 Oncologia Medica, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, 80131 - Napoli/IT
  • 12 Medical Oncology, Ospedale Santa Maria Goretti, 04100 - Latina/IT
  • 13 Medical Oncology, Ospedale Versilia USL12, 55041 - Lido di Camaiore (LU)/IT
  • 14 Oncologia Medica, USL4 Ospedale di Prato, 59100 - Prato/IT
  • 15 Oncologia Medica, AO Treviglio-Caravaggio, 20047 - Treviglio (BG)/IT
  • 16 Oncology, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 17 Operative Office, Nerviano Medical Service, 20014 - Nerviano (MI)/IT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3755


EOX (EPI + oxaliplatin-OHP + capecitabine-CAPE) is still one of the standard regimens for M or LA GC, but the role of EPI is today widely questioned and DOC replaced it in many institutions. A new DOC-based combination was developed with attempt at increasing efficacy/activity vs EOX without the heavy toxicity of the “classic” DOC regimen.


From 1/2013 to 11/2018, 169 previously untreated patients (pts) with M (87,6%) or LA GC were randomized by 23 centers between low-TOX (arm A) and EOX (arm B): Arm A: DOC: 35 mg/m2 iv, d 1 and 8 + OHP: 80 mg/m2 iv, d 1 + CAPE: 750 mg/ m2 x2 daily p.o. for 2 weeks Arm B: EPI: 50 mg/m2 iv, d 1 +OHP: 130 mg/m2 iv, d 1 +CAPE: 625 mg/m2 x2 daily p.o. for 3 weeks Both regimens recycled q 3 weeks If no PD or heavy toxicity, pts were programmed on therapy for a maximum of 5 (if CR) or 6 courses (if PR or SD). The primary endpoint was PFS, the secondary OS, ORR, DCR and tolerability. The study was designed to detect a 35% (80% power at a two side 5% significance level) PFS increase with low-TOX and an interim analysis for futility was planned after the first 127 events (75% of expected).


At the cut-off date of interim analysis, 164 pts (median age 62 y; 63,9% male; ECOG PS: 0 in 75,7%) have available data for evaluation of primary efficacy analysis. The median PFS (KM) was 5.8 months (95% CI: 5.0 – 7.8) in arm A vs 6.5 months (95% CI: 5.0 – 8.9) in arm B, without statistical difference (NS). Also OS was comparable in the two arms: 12.2 (95% CI: 8.6 -16.0) vs 12.8 months (95% CI: 9.1-21.0). ORR were 22% and 35.4% and DCR 59.8% and 65.9%, respectively, again NS. The median number of courses per patient was 6 and treatment modification was higher in arm A (90,2% vs 78%) with a weakly higher number of AE with CTC ≥ 3 in arm A (54 vs 41).


These results indicate that, on the basis of the planned futility analysis, it is unlikely that low-TOX regimen is able to reach the target of improvement against EOX, both in efficacy/activity and in tolerability. Therefore, if the clinician’s choice is in favour of a triplet (i.e. in aggressive or very symptomatic disease), EOX could remain a standard option.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study



Study carried out within the Rete Oncologica Lombarda-ROL project and founded as per the Deliberazioni di Giunta Regionale (DGR) di Regione Lombardia n° VIII/010761 dell’11-12-2009 e DGR IX/1485 del 30-03-2011”.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.